12 completed, 5 recruiting, 3 not yet recruiting, 2 active not recruiting. 23 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 12, Recruiting 5, Not yet recruiting 3, Active not recruiting 2, Terminated 1 |
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy IBI3034, Placebo, Telitacicept - IgA Nephropathy (IgAN) | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 100 | 2026-10-15 | 2026-10-21 |
| A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants Budesonide delayed release tablet - IgA Nephropathy | Phase 1 | Not yet recruiting | Triastek, lnc. | 18 | 2026-10-01 | 2026-10-27 |
| A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment RG002C0106 - Renal Impairments, IgA Nephropathy (IgAN) | Phase 1 | Active not recruiting | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | 24 | 2026-03-15 | 2026-10-15 |
| A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. MIL116, Matching Placebo - Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 130 | 2026-02-05 | 2026-04-13 |
| A Phase 1 Study of CLYM116 in Normal Healthy Volunteers CLYM116, Placebo - Healthy Volunteers | Phase 1 | Recruiting | Climb Bio, Inc. | 48 | 2025-12-02 | 2026-02-20 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2025-12-01 | 2026-02-03 |
| Study of BHV-1400 in IgA Nephropathy BHV-1400 - IgA Nephropathy | Phase 1 | Recruiting | Biohaven Therapeutics Ltd. | 20 | 2025-07-30 | 2026-06-23 |
| A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects HRS-5965 Capsules - IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 16 | 2025-06-30 | 2025-08-20 |
| A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases SCTC21C - IgA Nephropathy | Phase 1 / Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 99 | 2025-01-01 | 2025-01-14 |
| Study of ARO-CFB in Adult Healthy Volunteers ARO-CFB, Placebo - IgA Nephropathy | Phase 1 | Completed | Arrowhead Pharmaceuticals | 49 | 2024-04-05 | 2026-05-20 |
| Relative Bioavailability Study of HR19042 in Healthy Subjects HR19042 Capsule, Tarpeyo®, Budenofalk® - Primary IgA Nephropathy; Autoimmune Hepatitis | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 18 | 2023-12-27 | 2025-04-22 |
| A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects HS-10390 tablet, Placebo tablet - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 84 | 2023-05-23 | 2024-10-09 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject SHR-2010 injection, SHR-2010 injection placebo - IgA Nephropathy | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 61 | 2022-06-30 | 2023-03-23 |
| Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria ALXN1720 - Proteinuria | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2022-06-29 | 2023-06-29 |
| Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease ARO-C3, Placebo - C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 62 | 2022-02-01 | 2026-05-22 |
| A Trial of HR19042 Capsule in Healthy Chinese Subjects HR19042 capsule - Primary IgA Nephropathy | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 12 | 2021-07-01 | 2021-09-24 |
| Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension RE-021, sparsentan - Healthy Subjects | Phase 1 | Completed | Travere Therapeutics, Inc. | 47 | 2020-06-18 | 2022-09-30 |
| The Clinical Trial of ADR-001 for IgA Nephropathy infusion of ADR-001 (Mesenchymal stem cell) - Glomerulonephritis , IGA | Phase 1 | Completed | Nagoya University | 9 | 2020-06-15 | 2023-05-01 |
| Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses - IgA Nephropathy | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 103 | 2019-04-08 | 2026-06-16 |
Showing 20 of 23. Sign in to see all of them.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Glomerulosclerosis, Focal Segmental (3) · Proteinuria (3) · Kidney Diseases (2) · Lupus Nephritis (2) · Renal Insufficiency, Chronic (2) · Atypical Hemolytic Uremic Syndrome (1) · Autoimmune Diseases (1) · Churg-Strauss Syndrome (1) · Diabetic Nephropathies (1) · Glomerulonephritis (1) · Glomerulonephritis, Membranoproliferative (1) · Glomerulonephritis, Membranous (1) · Granulomatosis with Polyangiitis (1)
Female Urogenital Diseases (23) · Female Urogenital Diseases and Pregnancy Complications (23) · Immune System Diseases (23) · Male Urogenital Diseases (23) · Urogenital Diseases (23) · Autoimmune Diseases (22) · Glomerulonephritis (22) · Nephritis (22) · Urologic Diseases (22) · Kidney Diseases (21) · Skin and Connective Tissue Diseases (4) · Cardiovascular Diseases (3) · Connective Tissue Diseases (3) · Hemic and Lymphatic Diseases (3) · Pathological Conditions, Signs and Symptoms (3)
Budesonide (1) · Celecoxib (1) · Itraconazole (1) · Midazolam (1) · Rifampin (1) · avacopan (1) · sparsentan (1) · telitacicept (1)
Arrowhead Pharmaceuticals (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Alexion Pharmaceuticals, Inc. (1) · Alpine Immune Sciences, Inc. (1) · Amgen (1) · Beijing Mabworks Biotech Co., Ltd. (1) · Biohaven Therapeutics Ltd. (1) · Chengdu Suncadia Medicine Co., Ltd. (1) · Climb Bio, Inc. (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Hansoh BioMedical R&D Company (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Nagoya University (1) · Novartis Pharmaceuticals (1) · Osprey Pharmaceuticals USA, Inc. (1)
China (11) · United States (5) · South Korea (4) · United Kingdom (4) · Australia (3) · New Zealand (2) · Canada (1) · Georgia (1) · Germany (1) · Japan (1) · Puerto Rico (1) · Thailand (1)
Bryan Curtis, M.D. (1) · Esther Yoon, MD (1) · Hong Zhang (1) · Michelle Hladunewich, M.D. (1) · Shoichi Maruyama, MD, PhD (1) · Vincent Pichette, M.D., Ph.D. (1)
PMID 38299639, PMID 35570983, PMID 35692547, PMID 39186380, PMID 40297949, PMID 40482854, PMID 40936477, PMID 41805697, PMID 42275148
2018 (1), 2023 (1)